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Terms Definitions  
Antimicrobial Stewardship Program(ASP) The antimicrobial stewardship program 
promotes the appropriate use 
of antimicrobials (including antibiotics), 
improves patient outcomes, reduces microbial 
resistance, and decreases the spread of 
infections caused by multidrug-resistant 
organisms. 
Antimicrobial Resistance (AMR) Multidrug-resistant organisms are bacteria and 
other microorganisms that have developed 
resistance to antimicrobial drugs. Common 
examples of these organisms include MRSA 
(methicillin/oxacillin-resistant Staphylococcus 
aureus) and VRE (vancomycin-resistant 
enterococci). 
Multidrug-Resistant Organisms (MDRO) Multidrug-resistant organisms are bacteria and 
other microorganisms that have developed 
resistance to antimicrobial drugs. Common 
examples of these organisms include MRSA 
(methicillin/oxacillin-resistant Staphylococcus 
aureus) and VRE (vancomycin-resistant 
enterococci). 
Beta-Latamases Beta-lactamases (β-lactamases, also known 
as penicillinase) are enzymes (EC 3.5.2.6) 
produced by bacteria, that provide multi-
resistance to β-lactam antibiotics such 
as penicillins, Cephalosporins, cephamycins, 
and carbapenems (ertapenem), 
although carbapenems are relatively resistant 
to beta-lactamase 
 
Defined Daily Dose The defined daily dose (DDD) is a statistical 
measure of drug consumption, defined by 
the World Health Organization (WHO). It is 
used to standardize the comparison of drug 
usage between different drugs or between 
different health care environments. The DDD 
is not to be confused with the therapeutic 
dose or with the dose prescribed by a physician 
for an individual patient 
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PENILAIAN TERHADAP PELAKSANAAN PROGRAM PENGAWASAN 
ANTIMIKROBIAL  DAN HASILNYA DI HOSPITAL TERPILIH DI 
DAERAH MAKKAH, SAUDI ARABIA 
 
ABSTRAK 
 Penggunaan agen antimikrobial yang berlebihan dan tidak sesuai serta 
kawalan jangkitan yang lemah menyebabkan masalah kerintangan, memanjangkan 
tempoh hospitalisasi, peningkatan kos perubatan, dan kematian. Program pengawasan 
antimikrobial (PPA) merupakan suatu usaha kolaboratif untuk mengoptimakan 
penggunaan agen antimikrobial dalam institusi penjagaan kesihatan melalui strategi 
meningkatkan kualiti berasaskan bukti. Justeru, matlamat penyelidikan ini adalah untuk 
menilai kesan pelaksanaan program pengawasan antimikrobial dalam penjagaan 
kritikal bagi mengoptimumkan penggunaan agen antimikrobial, menjimatkan kos dan 
meningkatkan hasil klinikal di hospital terpilih di Makkah, Arab Saudi. Kajian ini 
dijalankan dalam tiga fasa. Fasa pertama adalah pendekatan penerokaan untuk 
menentukan mikroorganisma morbiditi yang paling lazim dalam isolat darah bagi 
pesakit di wad umum dan unit penjagaan kritikal (ICU & CCU), serta corak kerintangan 
di kalangan komuniti yang diperoleh patogen yang diasingkan dari penduduk Makkah. 
Selain itu, fasa ini juga bertujuan untuk meneroka faktor-faktor risiko yang berkaitan 
untuk jangkitan nosokomial Acinetobacter baumannii (MDR-AB) yang tahan multi-
ubat di hospital penjagaan tertiari, Makkah, Arab Saudi. Hasil kajian menunjukkan 
kejadian mikroorganisma Gram-negatif yang tinggi dalam CCU dan mikroorganisma 
Gram-positif dalam wad umum selama tempoh 12 tahun. Daripada 374 sampel isolat 
komuniti yang diperolehi, kerintangan tertinggi diperhatikan untuk amoxicillin / 
clavulanic acid. Dalam kajian kes kawalan yang dipadankan dengan hospital yang 
	
xvii 
dijalankan di hospital penjagaan tertiari, hasil regresi logistik pelbagai faktor risiko 
yang berkaitan dengan Acinetobacter baumanni (MDR-AB) tahan multi-ubat 
menunjukkan perkara berikut: pengimunotindasan (OR = 2.9; 95% CI 1.5-5.6; p = 
0.002), hasil klinikal (OR = 0.4, 95% CI 0.3-0.9; p = 0.01), prosedur invasif (OR = 7.9; 
95% CI 1.8-34.2; p = 0.002), kateter vena pusat (OR = 2.9, 95% CI 1.5-5.6; p = 0.000), 
dan tiub endotracheal (OR = 3.4; 95% CI 1.6-7.3; p = 0.001). Fasa kedua kajian 
mengukur tahap pelaksanaan dan keberkesanan program PPA di hospital-hospital di 
Makkah di peringkat farmasi dan di peringkat kebangsaan di kalangan pakar perubatan 
penjagaan kritikal KSA. Antara hospital yang mengambil bahagian, 19 (76 %), strategi 
yang paling lazim adalah, menghadkan formulari (90%) untuk agen antimikrobial 
spektrum luas dan penggunaan pesanan berhenti automatik (65%) untuk menghadkan 
terapi empirikal antimikrobial. Majoriti hospital tidak mempunyai garis panduan 
antimikrobial tempatan (90%) berdasarkan anti-biogram di seluruh hospital. 
Berdasarkan kaji selidik nasional di kalangan pengamal intensivis dewasa di ICU 
berasaskan universiti dan bukan universiti di Arab Saudi, dua puluh tiga (12%)  unit 
rawatan intensif tidak mempunyai program Pengawasan Antimikrobial. Manakala, 
sebanyak 161 (88%) ICU mempunyai program Pengawasan Antimikrobial. Strategi 
pengawalan yang paling lazim digunakan adalah pemantauan pakar perubatan 
berjangkit bersama dengan pasukan ICU (59.3%), audit dan maklum balas oleh ahli 
farmasi klinikal (22.9%). Ketersediaan data kerintangan antimikrobial oleh ahli 
mikrobiologi klinikal kepada pakar perubatan dapat digunakan untuk membimbing 
terapi empirik bagi jangkitan di kalangan masyarakat. Berdasarkan hasil tinjauan kami, 
pengamal intensivis di Arab Saudi menyokong program pengawasan antimikrobial di 
ICU dan berpendapat bahawa PPA menyediakan perkhidmatan yang berguna kepada 
kedua-dua pihak pesakit dan doktor.Dalam fasa ketiga, strategi pengawasan 
	
xviii 
antimikrobial pelbagai disiplin dilaksanakan di penjagaan kritikal 20 katil di sebuah 
hospital terpilih di Makkah, Arab Saudi. Analisis siri masa pengubahsuaian kawalan 
digunakan untuk membandingkan hasil dalam tempoh 9 bulan sebelum dan selepas 
pelaksanaan PPA. Ubat-ubatan yang digunakan untuk profilaksis Deep Vein 
Thrombosis (contohnya perencat pam proton / penyekat reseptor H2) digunakan 
sebagai ubat pengesan bagi Kumpulan Kawalan. Purata penggunaan agen antimikrobial 
bulanan diukur sebagai defined daily dose (DDD) setiap 100 hari katil dikurangkan 
sebanyak 25% (742.86 vs. 555; p<0.1) berbanding dengan kumpulan kawalan (ubat 
pengesan) sebanyak 7% (35 vs. 38;p<0.735). Menariknya, terdapat kesan negatif ke 
atas kos dalam fasa pasca intervensi. Menariknya, penggunaan IV Ceftriaxone diukur 
sebagai defined daily dose (DDD) setiap 100 hari katil dikurangkan sebanyak 82% (94 
vs 17; p<0.008), manakala penggunaan Vancomycin oral meningkat sebanyak 84% (27 
vs. 172; p< 0.0008) di ICU. Kadar penerimaan doktor untuk majoriti cadangan PPA 
adalah signifikan. Cadangan utama untuk mengoptimalkan penggunaan antibiotik 
dalam penjagaan kesihatan adalah penglibatan pihak pentadbir tertinggi daripada 
pelbagai disiplin ke dalam jawatankuasa PPA, melaksanakan audit harian dan 
maklumbalas oleh ahli farmasi dan pakar perubatan klinikal dengan latihan penyakit 
berjangkit, aktiviti pendidikan berterusan mengenai penggunaan antimikrobial dan 
masalah kerintangan, melaksanakan penyelidikan, penggunaan garis panduan tempatan 
dalam mempreskripsikan antimikrobial berdasarkan kepada anti-biogram terkini dan 
sokongan daripada pasukan penjagaan intensif.  
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EVALUATION OF ANTIMICROBIAL STEWARDSHIP PROGRAMS  
IMPLEMENTATION AND OUTCOMES IN SELECTED HOSPITALS AT 
MAKKAH REGION, KINGDOM OF SAUDI ARABIA 
 
ABSTRACT 
 
Antimicrobial stewardship programs (ASPs) are collaborative efforts to 
optimize antimicrobial use in healthcare institutions through evidence-based quality 
improvement strategies. The aim of this research was to evaluate the impact of ASPs 
in a critical care setting for improving antimicrobial use, cost efficiency and clinical 
outcomes at selected hospitals in Makkah, Kingdom of Saudi Arabia (KSA). In phase 
one study, an exploratory survey approach was adopted to determine the presence of 
morbidity caused by organisms in both out and in-patients blood isolates at two Saudi 
hospitals. Besides that, resistance pattern among community acquired pathogens such 
as the Multi Drug Resistant Acinetobacter Baumannii (MDR-AB) was also 
documented.  The findings from this phase suggested that there was high incidence of 
both gram positive and gram negative organisms in general wards over a 12 years 
period. In the same phase, results of multiple logistic regression of risk factors 
associated with Multidrug Resistant Acinetobacter baumanni (MDR-AB) were as 
follows: immunosuppression (OR = 2.9; 95% CI 1.5-5.6; p = 0.002), clinical outcome 
(OR = 0.4; 95% CI 0.3-0.9; p = 0.01), invasive procedure (OR = 7.9; 95% CI 1.8-34.2; 
p = 0.002), central venous catheter use (OR = 2.9; 95% CI 1.5-5.6; p = 0.000), and 
endotracheal tube use (OR = 3.4; 95% CI 1.6-7.3; p = 0.001). In the phase two study, a 
survey to explore current success and issues related to implementation of ASP programs 
in Makkah region hospitals at the pharmacy level (n = 23) and at the national level 
among critical care physician (n=382) were carried out. Among responding hospitals, 
respondents from 19 (76%) hospitals summarized ASP programs as following: 
	
xx 
formulary restrictions (90%) for broad-spectrum antimicrobials and use of automatic 
stop orders (65%) to limit empirical therapy of antimicrobials. In national survey 
among practicing intensivists across Kingdom of Saudi Arabia (n= 382), the following 
output were obtained (Response rate: 39%; n= 149): 27 (18 %) of them mentioned that 
their intensive care units had no ASP implemented, while 122 (82 %) of them had 
reported that their ICUs had Antimicrobial Stewardship program in place. In phase 3, 
an evaluation of a multidisciplinary ASP implemented in a 20-bed critical care setting 
carried out. A controlled interrupted time series analysis was used to compare outcomes 
in the 9 months before and after ASP implementation. The findings found that the mean 
total monthly antimicrobial consumption measured as defined daily dose (DDD) per 
100 bed days was reduced by 25 % (742.86 vs. 555; p = 0.1) compared to 7 % in the 
control group (tracer medications) (35 vs. 38; p = 0.735). Interestingly, there was a 
negative impact on cost in the post intervention phase. Interestingly, the use of IV 
Ceftriaxone measured as defined daily dose per100 bed days was decreased by 82 % 
(94 vs. 17; p = 0.008), whereas, oral Vancomycin use was increased by 84 % (27 vs. 
172; p = 0.008) in the ICU. Overall, based on the present study findings, involvement 
of higher administration in multidisciplinary ASP committees, daily audit & feedback 
by clinical pharmacist and physicians with infectious diseases training, continuous 
educational activities about antimicrobial use and resistance, use of local antimicrobial 
prescribing guidelines based on up to date anti-biogram and support from intensive care 
team are key sets of recommendations that can be made to enhance quality use of 
antibiotics in Saudi healthcare institutions. 
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CHAPTER ONE: GENERAL INTRODUCTION 
 
1.1 Background  
Antimicrobial resistance (AMR) is a health risk worldwide and the main cause of 
health-related morbidity and mortality (J. E. McGowan, 2012). One reason is the 
development of MDR organisms (MDROs), which are associated with irrational and 
excessive antimicrobial prescribing behaviour (A. R. Marra et al., 2009). The incidence 
of MDROs is growing despite tight infection control strategies. Infections due to 
MDROs are associated with deterioration in clinical outcomes and increase the 
financial burden in healthcare settings. Cosgrove et al. found that cephalosporin-
resistant Enterobacter infections enhanced mortality and the length of hospitalization 
and increased cost (Sara E Cosgrove, Kaye, Eliopoulous, & Carmeli, 2002). During 
hospitalization, up to 60% of all hospitalized patients in the United States received one 
dose of antibacterials during their stay. Up to 50% of such treatments are considered 
unnecessary or otherwise inappropriate, which may include the following (S. E. 
Cosgrove & Carmeli, 2003; Gerding, 2001; MacDougall & Polk, 2008; Vogtlander et 
al., 2004): 
1 Treating non-bacterial infections 
2 Treating colonization and contamination due to poor sampling technique  
3 Recommending broad-spectrum antibiotics where narrow-spectrum drugs can 
be used effectively 
4 Longer duration of therapy and  
5 Lack of dose optimization, e.g., for vancomycin and aminoglycosides 
Antimicrobial drug use is at least partially responsible for rising infections due to 
resistant organisms and has become a serious concern in the last decade (Sievert et al., 
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2013). Additionally, resistance has emerged even to more potent organisms, e.g., 
Carbapenem-Resistant Enterobacteriaceae (CRE) and metallo-ß-lactamase-producing 
Enterobacteriaceae. These strains are responsible for 50% of the infectious disease-
related mortality in the United States. In addition, these resistant strains carry genes 
that may transfer resistance to other antimicrobial agents (Ben-David et al., 2010). 
The diminishing development of new antimicrobials and the emergence of resistance 
emphasizes that we must optimize the use of current antimicrobials via the 
implementation of surveillance programs, e.g., formulary restrictions and prospective 
auditing and feedback in healthcare institutions (Hersh et al., 2015; B. Spellberg et al., 
2008). These approaches are supported by most of the official governing bodies in 
infectious diseases societies (B. Spellberg et al., 2011).  Furthermore, in 2013, as per 
the Infectious Diseases Society of America (IDSA), to prolong antibiotic effectiveness, 
implementation of antimicrobial stewardship programs (ASPs) in healthcare 
institutions was one of the strategies to combat resistance (Bartlett, Gilbert, & 
Spellberg, 2013) and discourage the spread of resistant bugs in healthcare systems 
(Barlam et al., 2016; Dellit et al., 2007). Further, ASPs enhance the prescriber’s 
adherence to treatment guidelines and result in appropriate antibiotics selection in 
clinical settings (Ansari et al., 2003; Bauer et al., 2010; Brink et al., 2016; R. Kaki et 
al., 2011).  
Every institution uses a specific stewardship program with specific patient outcomes. 
The most common outcomes studied in various stewardship programs are a reduction 
in total antimicrobial use in an institution, decrease in inappropriate antimicrobial use, 
decrease in the infection-associated length of stay, decrease in infectious-related 
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mortality and decrease in overall AMR patterns in an institution (Jacobs, Kuper, 
Septimus, Arafat, & Garey, 2014; C. MacDougall & R. E. Polk, 2005)  
Several surveys have been conducted globally and reported many types of antimicrobial 
stewardship strategies in health institutions. Howard et al., based on a globally 
administered survey, concluded that the majority (52%) of the institutions follow 
national prescribing guidelines and that most (58%) are implementing antimicrobial 
stewardship activities. Lack of personnel and information technology services were the 
major barriers in stewardship implementation (Howard et al., 2015).  
1.2 Defining Antimicrobial Stewardship 
Antimicrobial drugs are individual agents that do not directly affect patients while 
affecting the growth of microorganisms and thus curing infectious diseases caused by 
invading pathogens (C. Pulcini, 2014). Antimicrobial use is the key driver of AMR. 
Misuse of antibiotics, including unnecessary prescription and inappropriate use 
(inadequate dosing, incorrect pharmacokinetics and inappropriate duration according 
to patient characteristics) may lead to the development of AMR and is a major threat to 
public health. In 2003, Hecker et al. found that approximately 60% of the patients in 
the United States received at least one dose of antibiotics during hospitalization, and 
half of these instances were inappropriate (Hecker, Aron, Patel, Lehmann, & Donskey, 
2003). Therefore, more prudent use of antimicrobial agents can slow or reverse the 
development of resistance (MacDougall & Polk, 2008). AMR is a considerable public 
health threat and is associated with a higher incidence of mortality and prolonged 
hospital stays. One of the reasons underlying this problem is the development of 
MDROs related to irrational and excessive prescriptions of antimicrobials (A. R. Marra 
et al., 2009). 
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This epidemic increase in antibiotic-resistant bacteria has led to the need to reduce 
excessive antibiotic use, especially during emergency department visits for community-
acquired infections, e.g., acute respiratory infections, where a substantial number of 
antibiotics are prescribed for illnesses that do not require antibiotics clinically. 
Therefore, initial antimicrobial selection in acute care settings is of paramount 
importance in treatment success (Gonzales et al., 2001; S. Harbarth et al., 2003; M. 
Kollef, 2003; Kumar et al., 2006). 
 In recent years, there has been a rapid drop in antibiotic response against common 
infections. The diminishing investment in the development of new antimicrobials 
potentiates this concern and necessitates the adoption of strategies and programs in 
healthcare settings to optimize currently available antimicrobial use (Rice, 2008; Brad 
Spellberg, Powers, Brass, Miller, & Edwards, 2004). According to the Infectious 
Disease Society of America and the Society for Healthcare Epidemiology, the 
frequency of inappropriate antimicrobial use is a surrogate marker for the avoidable 
impact on AMR. Therefore, to promote the optimum use of antimicrobials and conserve 
their worth in healthcare settings, it is recommended by many regulatory agencies to 
develop a rational, systematic approach to the use of antimicrobial agents (Dodds 
Ashley, Kaye, DePestel, & Hermsen, 2014). 
To achieve this goal and guide antimicrobial use through antimicrobial stewardship 
strategies, it is necessary to change the attitudes of prescribers (Friedman, 2013). The 
main paradigms of antimicrobial use include acute infections among outpatients and 
inpatients, chronic infections and veterinary medicine. Optimizing antimicrobial use in 
these disciplines requires knowledge of the outcomes associated with this misuse and 
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the effectiveness of strategies to overcome associated consequences (A. R. Marra et al., 
2009).  
Antimicrobial stewardship refers to coordinated interventions designed to improve and 
measure the appropriate use of antimicrobials (Fishman, 2012). ASPs are overarching 
programs of policies, management programs and control programs directed at 
improving antimicrobial use, resistance and clinical outcomes. Antimicrobial 
stewardship is a multidisciplinary approach involving multiple strategies to optimize 
antimicrobial use, e.g., dose optimization for antimicrobials based on drug 
pharmacokinetics/pharmacodynamics (PK/PD) programs, intravenous to oral 
switching of antimicrobials, de-escalation/streamlining of antimicrobials, and 
formulary restriction strategies (C. MacDougall & R. E. Polk, 2005; R. C. Owens, Jr., 
2008).  Therefore, establishing an ASP is of prime importance as it has great potential 
to promote judicious antimicrobial use in healthcare institutions. 
1.3 Antimicrobial Stewardship Strategies 
Every institution uses a specific stewardship program with specific patient outcomes. 
The most common outcomes studied in various stewardship programs are the reduction 
in total antimicrobial use in an institution, decrease in inappropriate antimicrobial use, 
decrease in infection-associated length of stay, decrease in infection-related mortality 
and decrease in the overall AMR pattern in an institution (Jacobs et al., 2014; Conan 
MacDougall & Ron E Polk, 2005; R. C. Owens, Jr., 2008).  
Several surveys have been conducted globally and reported many types of antimicrobial 
stewardship strategies in health institutions. Howard et al., based on a global 
antimicrobial stewardship survey, concluded that national antimicrobial stewardship 
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standards were implemented in only 52% of the hospitals, while 58% were planning to 
implement antimicrobial stewardship activities in their institutions. Major barriers to 
ASP implementation were lack of personnel and lack of information technology. 
Antimicrobial restriction was the most implemented strategy among institutions with 
ASPs (Howard et al., 2015). 
According to the IDSA, there are two core antimicrobial stewardship strategies: 
prospective audit with intervention, and feedback and formulary restrictions and 
preauthorization. Both strategies are proactive and are not mutually exclusive. 
Depending on the local practice patterns and resources, additional programs can be 
considered to gain maximum benefit from these strategies. Supplementary programs 
might include education, guidelines/clinical pathways, antimicrobial order forms, de-
escalation of therapy, dose optimization, and IV to oral conversion (Barlam et al., 2016; 
Dellit et al., 2007).  
The prospective audit is usually performed by an infectious diseases physician or 
clinical pharmacist and is an effective strategy to prevent excessive antimicrobial use. 
In some instances, such audits can be practised retrospectively to develop interventions 
based on findings in an institution. The main advantage of this strategy is to maintain 
prescriber autonomy and provide educational opportunities. One of the major 
drawbacks of this strategy is a reluctance of prescribers to change therapy if a patient 
is doing well on initial therapy, and the retrospective nature of the study permits 
inappropriate exposure. Furthermore, in some instances, it may be difficult to identify 
the decision-making team with this strategy (Dellit et al., 2007; Hermsen et al., 2014). 
Formulary restriction and preauthorization are another highly recommended effective 
stewardship activity. The main objective of this strategy is to control the overuse of 
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broad-spectrum antimicrobials. Pre-authorization is required for most last-line 
antimicrobials to limit their misuse for severe infectious diseases. The most common 
disadvantage of this activity is the potential delay in therapy that may indirectly affect 
clinical outcomes. In addition, there is a limited role of infectious diseases 
physicians/clinical pharmacists in this strategy (Micek, Ward, Fraser, & Kollef, 2004). 
In addition to the core strategies, there are additional recommendations that can support 
and facilitate the implementation of core strategies. National and international 
authorities recommend optimizing the knowledge of physicians through education 
about infectious diseases to promote prudent antimicrobial use (Barlam et al., 2016). 
Educational strategies can influence prescribing behaviour and promote the acceptance 
of antimicrobial stewardship in an institution. Most educational strategies often require 
a long time and consistency to achieve outcomes (Céline Pulcini & Gyssens, 2013). As 
per the WHO statement issued for the World Health Day 2011, educational strategies 
should target both patients and healthcare practitioners to prevent unnecessary 
antibiotic prescription (Leung, Weil, Raviglione, & Nakatani, 2011). 
One type of evidence-based educational strategy is to create protocols to guide 
antimicrobial use for a given infection. This strategy can include the inclusion of locally 
developed guidelines based on specific patient populations and resistance patterns. The 
most important concern regarding pathways/guidelines is compliance, which in most 
cases is voluntary and depends on personal awareness. According to new international 
guidelines, there is a need for the on-going maintenance of pathways. The development 
of antimicrobial order forms can support guidelines and pathways for specific 
infectious diseases, e.g., pneumonia, sepsis, and surgical prophylaxis. Meyer et al. 
found that an implementation and enforcement of pneumonia treatment guidelines in 
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the ICU resulted in a 50% reduction in treatment duration and a 30% reduction in 
antibiotic consumption and costs. Connor et al. studied the consequences of a 72-hour 
automatic stop order and found it an effective strategy for antimicrobial stewardship 
(Connor et al., 2007). 
Refailidis et al. provided an informative review of the optimal duration of therapy for 
acute respiratory infections based on a meta-analysis. He concluded that the duration 
of antimicrobial therapy could be shortened without compromising outcomes 
(Rafailidis, Pitsounis, & Falagas, 2009). 
De-escalation, narrowing the spectrum of activity as appropriate based on 
culture/susceptibility results and clinical response, also supplements antimicrobial 
control. This activity may influence future prescribing patterns indirectly and can 
decrease inappropriate antimicrobial use while lessening the risk of adverse events. 
Physician resistance is a notable concern in this strategy, as prescribers may be reluctant 
to change therapy if the patient is doing well. In addition, there might be a chance of 
inappropriate narrowing of the spectrum based on the gram staining strategy (Drew et 
al., 2009; Eachempati, Hydo, Shou, & Barie, 2009; Rello et al., 2004). De-escalation 
also produces economic outcomes regarding cost minimization in antimicrobial therapy 
(Deresinski, 2007).  
It is often a possibility that an antimicrobial is initiated appropriately and promptly but 
without pharmacokinetic and pharmacodynamic considerations. This may lead to the 
failure of therapy, as in many cases, there is a specific MIC (minimum inhibitory 
concentration) to eradicate the organism, minimize toxicity, and prevent resistance. 
Therefore, there must be a specific dose of antimicrobials based on pharmacokinetics 
parameters. This strategy will also impact future prescribing behaviour and thus limit 
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irrational antimicrobial use in acute care settings. In some instances, this strategy may 
enhance pharmacy and nursing time (DePestel et al., 2014; Lodise, Patel, Lomaestro, 
Rodvold, & Drusano, 2009). 
1.4 Antimicrobial Stewardship in Critical Care Settings 
Critical care facilities in healthcare institutions host most of the vulnerable patient 
population suffering from multiple disorders and having multiple catalysts to spread 
resistance, e.g., loss of physiological barriers and high antibiotic pressure. Furthermore, 
severe infections are most common in intensive care units and require careful 
management to improve patient outcomes. ASPs in critical care settings must ensure 
specific goals and strategies to promote rational antibiotic use promptly to treat life-
threatening infections. An ICU ASP may exhibit some very ICU-specific goals and 
strategies (Brusselaers, Vogelaers, & Blot, 2011; Reham Kaki et al., 2011; Taggart, 
Leung, Muller, Matukas, & Daneman, 2015).  
Antimicrobial stewardship implementation in intensive care units is quite challenging 
for the multidisciplinary team, e.g., I.D. physician, clinical pharmacist, and clinical 
microbiologists, as in critical care settings patient care involves a closed format where 
the intensivist takes responsibility for patient care and does not allow other 
professionals to intercede. Therefore, routine audit and feedback activity in clinical 
rounds is a suitable ASP activity in critical care settings. In addition, regular provision 
of AMR data and antibiotic use can develop a trust relationship in intensive care settings 
(M. H. Kollef & Micek, 2012; Kevin L Lawrence & Marin H Kollef, 2009; Taggart et 
al., 2015).  
Timely recognition of infections is also a diagnostic challenge in critically ill patients, 
as signs and symptoms of inflammation might be conflated with infection signs and 
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mislead management. Clinical decision support and biomarkers triggering treatment 
algorithms are few advancements enabled by antimicrobial stewardship 
implementation in critical care settings. Clinical decision support to improve 
antimicrobial prescribing is evidenced by very limited studies. A landmark study by 
Evans et al., in Utah demonstrated the efficacy of CDSS in the ICU. The programs 
guide prescribing teams with antimicrobial selection and prompt feedback upon 
provision of patient’s clinical data. Once the organisms is identified, recommendation 
for the correct choice of antimicrobial was provided by correlation with hospital based 
anti-biogram automatically. This program produced significant reduction in excessive 
drug dosages (87 vs. 405, p<0.01) and antibiotics susceptibility mismatches (12 vs 206, 
P<0.01). In addition, there was substantial reduction in the cost of antiinfective agents 
(adjusted mean, $102 vs. $427 and $340, respectively; P<0.001), in total hospital costs 
(adjusted mean, $26,315 vs. $44,865 and $35,283; P<0.001), and in the length of the 
hospital stay (adjusted mean, 10.0 vs. 16.7 and 12.9 days; P<0.001) (Evans et al., 1998).  
Further, viral infections are more common in critical care settings and need careful 
diagnosis to initiate antimicrobial therapy. The use of pro-calcitonin and C-reactive 
protein levels is another advancement in antimicrobial stewardship strategies to guide 
appropriate antibiotics therapy (Barlam et al., 2016; K. L. Lawrence & M. H. Kollef, 
2009; Simon, Gauvin, Amre, Saint-Louis, & Lacroix, 2004; Singer et al., 2016).  
In critical care settings, another challenge is the initiation of empirical antimicrobial 
therapy appropriately based on patient characteristics, site of infection, patient age, 
hepatic and renal function, previous antibiotics use and length of hospitalization. In 
addition, local colonization status with MDROs plays an important role in determining 
the initial antimicrobial therapy. Further, antimicrobial therapy in CCUs should be 
based on local anti-biogram-based treatment guidelines to prevent certain delays in 
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culture sensitivity results (Battleman, Callahan, & Thaler, 2002; Depuydt et al., 2006; 
Nseir et al., 2010).  
As critically ill patients are haemodynamically unstable with variable organ 
functionality, the role of PK/PD is crucial in deciding patient-specific dosing. In 
PK/PD-optimized therapy, a stepwise approach is advised, e.g., selection of the PK/PD 
target for antibiotics and choosing pharmacokinetics-based loading and maintenance 
doses to sustain a steady-state plasma concentration of specific antibiotics. The PK/PD 
model is best applied to vancomycin and aminoglycoside antibiotics to achieve 
maximum therapeutic effects within a safe range (Roberts & Lipman, 2009; Tsai, 
Lipman, & Roberts, 2015).  
 Antimicrobial de-escalation is an approach to limit broad-spectrum antibiotics use and 
to target the causative pathogen. De-escalation is an important antimicrobial 
stewardship strategy in the ICU. However, de-escalation of current antimicrobial 
therapy is quite challenging in critical care settings, as intensivists are resistant to 
changing an effective broad-spectrum therapy. The sepsis campaign guidelines 
recommend initiating broad therapy within the first hour of the onset of sepsis and daily 
reassessment for potential de-escalation of therapy (Diane Ashiru-Oredope, Sharland, 
Charani, McNulty, & Cooke, 2012; Leone et al., 2014; Singer et al., 2016; Tabah et al., 
2015). Therefore, de-escalation is a beneficial strategy in critical care settings to limit 
excessive broad-spectrum antimicrobial use.  
The duration of antibiotics therapy in critical care settings is a striking ASP strategy if 
we want to reduce antimicrobial exposure in critically ill patients (Barrett, Edgeworth, 
& Wyncoll, 2015). It is also a challenging intervention in the ICU, as the patient may 
be improved from infection but not fully recovered from organ dysfunction. This 
phenomenon may mislead intensivists, and therapy might go beyond the required 
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duration. Therefore, implementation of biomarkers, e.g., serial pro-calcitonin and C-
reactive protein measurement, can aid the ASP team to limit the length of antibiotic 
therapy. The cost-effectiveness of pro-calcitonin is still controversial, notwithstanding 
its effectives in limiting excessive antibiotic therapy. A multi-centre, prospective, 
parallel-group study conducted by Bouadama et al. concluded that “procalcitonin 
guided therapy in intensive care units may reduce antibiotics exposure and selective 
pressure without adverse outcomes”  (Bouadma et al., 2010).  
In conclusion, antimicrobial stewardship implementation in critical care settings 
involves special considerations regarding the patient population in such critical settings 
and requires an evidence-based approach to develop a trust relationship with 
intensivists. Therefore, for the successful implementation of an ASP, it is a prerequisite 
to assess current practice and antibiotics use and then define the importance of rational 
antibiotics use in critical settings. Consumption of restricted antibiotics such as 
carbapenems and glycopeptides, e.g., vancomycin, linezolid and colistin, measured as 
DDDs per 1000 patient days, will inform intensivists about ASP efforts and convince 
them of the value of ASP implementation.  
1.5 Study Justification 
Holy Makkah is of great importance in the Muslim world, and millions of pilgrims visit 
Makkah from various nations to perform Umrah and Hajj rituals. The majority of the 
pilgrims visit acute care settings and seek urgent care for acute infectious diseases, e.g., 
bronchitis, URTI, and community-acquired pneumonia (Z. A. Memish et al., 2014; S. 
Yezli, Shibl, Livermore, & Memish, 2012).   
The most common causes of acute hospital admissions among Makkah residents, 
including pilgrims, are respiratory, cardiovascular, and gastrointestinal disorders. The 
highest incidence of admissions is related to respiratory disorders, including pneumonia 
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(39.4%) and the exacerbation of asthma and chronic obstructive pulmonary diseases 
COPD (14.4%). The most common comorbidities are hypertension, asthma, COPD, 
and diabetes mellitus (Al Shimemeri, 2012; Madani & Ghabrah, 2007).   
The majority of antibiotics prescribed are for acute care, often as a treatment for 
respiratory tract infections, making them a major contributor to AMR. Resistance may 
result from the uncontrolled and indiscriminate use of antibiotics from this sector 
(Karabay et al., 2011).  
To the best of our knowledge, there is limited literature describing the successful 
implementation and effectiveness of antimicrobial stewardship strategies in critical care 
settings in the KSA in general and in the Makkah region hospital settings dealing with 
Saudis and Hajj/Umrah pilgrim populations specifically. In addition, there are no data 
highlighting community-acquired AMR risk among Makkah residents. The general 
administration of pharmaceutical care in 2013 initiated the process of antimicrobial 
stewardship implementation at the Ministry of Health (MOH) hospitals primarily and 
later expanded it to all medical institutions. The administration has developed a five-
year plan to implement stewardship in MOH hospitals. This program has completed the 
initial phases and is in the data-collection stage at selected hospitals, primarily in the 
central region in Riyadh and later to be completed in other regional hospitals (Alomi, 
2017).  
The whole scenario necessitates a detailed study of the prevalence of community-
acquired organisms isolated from samples obtained from Makkah residents, including 
Hajj and Umrah pilgrims, suffering from community-acquired infections and their 
resistance pattern against commonly used antibiotics in order to develop an evidence-
based ASP to treat common infections in critical care settings dealing with acute 
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admissions. The outcomes of the study will also be of pivotal importance to devise 
policies and strategies for antimicrobial stewardship implementation in other settings 
in the Makkah region.  
1.6 Study Objectives  
Phase 1: To determine the extent of antimicrobials reporting and community  
                acquired resistance at selected hospitals in the Makkah region  
i To assess the prevalence of bloodstream infection-causing pathogens and 
community acquired AMR for selected organisms at selected hospitals in 
Makkah, KSA.  
ii  To identify risk factors associated with MDR-AB nosocomial infections at 
a tertiary care hospital in Makkah, KSA. 
Phase 2: To determine ASP success in hospitals in the KSA and  
                 their perceived level of success 
i To identify ASPs in Makkah region hospitals and their perceived level of 
success.   
ii To assess critical care physician knowledge, attitudes and perceptions of 
ASP implementation in critical care settings in the KSA.  
Phase 3: Antimicrobial stewardship implementation in a critical care setting in a  
                selected hospital in Makkah, Kingdom of Saudi Arabia  
i To study the impact of ASP implementation on process, economical and 
clinical outcomes in a critical care setting by using a quasi-experimental 
study design in Makkah, KSA.  
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1.7 Thesis Overview  
This thesis consists of nine chapters, covering an introduction, methods, results, and 
discussion. Chapter two, the literature review, starts with definitions of AMR 
mechanisms in bacteria and focuses on clinically prominent pathogens requiring 
attention at the global level. The chapter continues with an overview of antimicrobial 
stewardship core evidence-based strategies and their importance in clinical settings. 
Further discussion in this chapter proceeds with the role of the pharmacist in the 
efficient delivery of ASPs. The literature review finishes with a discussion of 
antimicrobial stewardship efforts at the global level and their relation to the current 
status of antimicrobial stewardship in the Middle East in general and in the KSA 
specifically. A detailed review of literature related to this study, looking at recent 
resistance threats and antimicrobial stewardship efforts in the KSA and elsewhere in 
the world, forms the bulk of this chapter.  
Chapter 3 comprises a detailed discussion of the study methodology, and in particular, 
possible methodological approaches in each study phase to achieve study-specific 
objectives. Chapter three also highlights the study objectives according to the study 
phases. Chapters 4 and 5 are consolidated as phase 1 of the study to highlight 
antimicrobial use resistance patterns among isolated organisms from Makkah residents 
of multiple nationalities. Chapter four describes the findings related to commonly 
reported organisms in a tertiary care hospital and their prevalence in general wards and 
critical care areas and presents findings on the resistance patterns of community-
acquired organisms isolated from Makkah residents attending two acute care settings 
for community-acquired infections. Chapter five presents findings from a matched case 
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control study addressing risk factors for MDR-AB-associated infections in the intensive 
care unit. 
Chapters 6 and seven are consolidated in phase 2 of the study to highlight existing ASPs 
in the Makkah region and at the national level in critical care settings. Chapter six 
describes existing ASPs in the Makkah region and their level of success. Further, 
Chapter seven describes the knowledge, attitudes and perceptions of critical care 
physicians regarding ASP implementation in critical care settings at the national level. 
Findings from phase one and two form the basis for the implementation of ASPs in a 
critical care setting dealing with admissions from a pilgrim population in Makkah City.  
Chapter 8 describes the intervention phase of the study. It describes the process of 
antimicrobial stewardship implementation in a critical care setting based on phase 1 
and two findings. This chapter provides findings of the impact of implementation of 
ASP on process, clinical and economic outcomes. Lastly, Chapter nine draws the thesis 
to a conclusion with an overall summary, study limitations and a set of 
recommendations for further research.  
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CHAPTER TWO: LITERATURE REVIEW 
 
2.1 Antimicrobial Resistance: A Global Healthcare Threat 
2.1.1 Introduction 
In recent years, there has been a rapid decline in the effectiveness of antibiotics in 
treating common infections, and with the influx of untreatable strains of CRE, we are 
almost at the brink of a post-antibiotic era. Below-optimum dosing of antibiotics 
facilitates the stepwise selection of resistance, and the spread is eased by inter-species 
gene transmission, poor hygiene and sanitation in communities and hospitals and 
increasing rates of global travel, trade, and disease transmission (Laxminarayan et al., 
2013). Nosocomial infections have a significant role in the transmission of resistant 
organisms; however, community infections contribute equally, as nearly 80% of 
antibiotic prescribing is done at the community level. The majority of admitted patients 
continue to carry extended-spectrum β-lactamase (ESBL)-producing 
Enterobacteriaceae over long  periods (Arpin et al., 2003). The ESBLs are enzymes 
generated by gram-negative bacteria (GNBs) that arbitrate resistance to cephalosporins, 
penicillins, and monobactams. MDR ESBLs and carbapenem-resistant ESBL isolates 
pose substantial therapeutic challenges (Vaidya, 2011).  
Mass gatherings such as the Hajj and Umrah may lead to serious health hazards from 
and among pilgrims via the transmission of diseases, especially infections that spread 
via contact, food or water contamination or respiratory droplets, an oral-faecal route or 
through vectors. Propagation of drug-resistant organisms during the Hajj is of the 
highest concern possible (Al-Tawfiq & Memish, 2015). During the Hajj, millions of 
pilgrims of multiple nationalities visit holy sites in Holy Makkah and Madinah. The 
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majority of the pilgrims are from Asian countries, e.g., India, Pakistan, and Bangladesh. 
Antibiotic resistance is a global issue but is quite prevalent in countries such as India, 
Pakistan, the KSA, Afghanistan, Bangladesh, and African countries (Atif H Asghar & 
Hani S Faidah, 2009; Idress, Mussarat, Badshah, Qamar, & Bokhari, 2010; Kader & 
Kumar, 2004; Oberoi, Singh, Sharma, & Aggarwal, 2013; Rath, Dubey, Sahu, Debata, 
& Padhy, 2014). There is a high risk of transfer of resistant organisms from pilgrims 
from such countries during travel. For instance, international transmission of New 
Delhi metallo-β-lactamase (NDM-1) has been confirmed in several countries 
(Nordmann, Poirel, Walsh, & Livermore, 2011), and ESBL bacteria transmission has 
been associated with international travel (van der Bij & Pitout, 2012). Therefore, it is 
imperative to highlight antibiotic use and resistance patterns among pilgrims to develop 
effective strategies to treat infectious diseases during the Hajj and Umrah season.  
2.1.2 Mechanisms of Antimicrobial Resistance 
Bacteria can develop resistance to antibiotics in several ways: intrinsic resistance to 
antibiotics or through spontaneous mutations in bacterial genes or the acquisition of 
new resistant genes. Intrinsic resistance is independent of antibiotic selective pressure 
and horizontal gene transfer. It may be associated with a lack of affinity of antibiotics 
for the bacterial site, the permeability of the drug into the bacterial cell or the presence 
of drug-destroying enzymes. In acquired resistance, previously sensitive bacteria 
develop resistance to antibiotics. This adaptation can be due to the mutation of a 
particular gene or transfer of a resistant gene via conjugation or transduction. Acquired 
resistance can be caused by the variable intracellular concentration of antibiotics due to 
low intake or increased efflux activity, genetic mutation of the bacterial chromosome 
and modification of the antibiotic by hydrolysis or modification of the binding site (A. 
H. Holmes et al., 2016; Principe et al., 2013).  
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In clinical practice, knowledge of the mechanism of resistance will ensure the optimal 
use of antibiotics and prevent the risk of acquired resistance. For example, polymyxin 
antibiotics are used as the last agent for many MDROs. GNBs, e.g., Acinetobacter 
baumannii and Pseudomonas aeruginosa, acquire resistance against polymyxin 
antibiotics, whereas bacteria such as Proteus spp., Serratia spp., and Burkholderia spp. 
are naturally resistant to these drugs (Olaitan, Morand, & Rolain, 2014).  
2.1.3 Antimicrobial Resistance among Gram-Positive and Gram-Negative 
          Bacteria: Global Perspective 
The declining usefulness of antibiotics in recent years and the introduction of CRE have 
nearly taken us to a post-antibiotic era (Jacob et al., 2013). In under-developed and 
developing countries, increased hospital stays and soaring rates of nosocomial 
infections are the major reasons for resistant strains and resistance. Moreover, 
mutations, irrational prescribing and suboptimum doses of antibiotics are contributing 
factors to resistance. Resistance is present on chromosomal and extra-chromosomal 
elements. The global spread of resistant clones, e.g., Escherichia coli ST131, 
methicillin-resistant Staphylococcus aureus (MRSA), and Klebsiella ST258, are a few 
examples of this grave scenario (Laxminarayan et al., 2013). 
The development of resistance in bacteria is evident from β-lactamases, with nearly 
1000 types that incapacitate these β-lactam antibiotics (19). The spread of resistance 
genes such as Enterobacteriaceae generating ESBL, NDM-1, and Klebsiella 
pneumoniae carbapenemase (KPC) shows the ease of transmission of resistance. In this 
respect, healthcare facilities play a major role in the swift spread of resistant clones. 
Enterobacteriaceae resistance against carbapenem is rapidly increasing. Even in 
countries such as the USA, 4.6% of acute-care hospitals in 2012 reported at least one 
health-care linked infection from CRE (Jacob et al., 2013). This trend of booming 
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resistance is more prevalent in developing countries. For instance, the WHO-
recommended ampicillin and gentamicin regimen for neonatal infections is 
encountering resistance, with 71% of Klebsiella spp. isolates and 50% of E. coli 
showing gentamicin resistance (Zaidi et al., 2005). ESBL production in E. coli has 
accelerated and is blunting second-line treatment with extended-spectrum 
cephalosporins. There are reports from Pakistan of pan-resistant CRE and 
Acinetobacter spp. (Perry et al., 2011; Saleem, Ahmed, Mir, Ali, & Zaidi, 2009). This 
resistance is also prevalent in Africa, with 50–60% of community-acquired gram-
negative microbes such as E. coli linked with UTIs with resistance to amoxicillin, 
cefixime, and ciprofloxacin (Laxminarayan et al., 2013). Adding more problems to the 
situation are reports of NDM-1, first identified in 2011 in South Africa (Lowman et al., 
2011). 
Since 2000, there has been a global dissemination of ESBL-producing 
Enterobacteriaceae, largely through E. coli and K. pneumoniae. Typical ESBLs are 
plasmid-borne β lactamases conferring resistance to cephalosporins, penicillins, and 
monobactams. ESBL producers are inhibited by clavulanic acid in vitro. Enzymes 
triggering this phenotype are frequently of the CTX-M type, and E. coli-producing 
CTX-M are increasing in healthcare centres as well as at the community level globally. 
At present, more than one hundred types of CTX-M β-lactamases have been recognized 
that are grouped into five main categories on the basis of their amino acid sequences. 
The phenomenon of co-resistance to other antibiotics is another main issue related to 
these ESBL producers generating MDR strains. ESBL-producing E. coli are frequently 
resistant to trimethoprim–sulfamethoxazole, aminoglycosides and quinolones that have 
been reported from around the world. Mechanisms of resistance to quinolones in 
Enterobacteriaceae were considered to be only encoded on chromosomes, but the 
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appearance of the qnr (qnrA, B, C, D, S, and variants) gene family on plasmids and its 
global presence and reports in E. coli and K. pneumoniae are serious concerns. Plasmid-
encoded qnr genes often co-exist with ESBL genes, and the horizontal transfer of 
plasmids harbouring these resistance genes concurrently may result in MDR strains 
(Balkhed et al., 2013). 
The continuous spread of MDR pathogens globally is responsible for major clinical, 
humanistic and economic consequences. It is estimated that drug-resistant bacteria are 
responsible for one death every ten minutes in the United States and Europe because of 
the development of life-threatening infectious diseases (Harbarth et al., 2015). These 
pathogens are resistant strains of both gram-positive and gram-negative strains in 
addition to drug-resistant fungal organisms. 
The most clinically important resistant gram-positive bacteria (GPBs) are MRSA and 
vancomycin-resistant enterococci. One of the reasons behind the spread of these 
pathogenic organisms is poor infection control measures at the hospital level 
(Organization, 2014). According to the European Centers for Disease Prevention and 
Control (CDC) AMR surveillance report in 2014, MRSA prevalence was decreasing in 
comparison to previous trends reported in 2012. A total of 6 out of 29 countries (Italy, 
Cyprus, Greece, Malta, Portugal, Romania) reported invasive MRSA isolates above 
30%. In addition, vancomycin-resistant enterococci strains are reported more in Europe 
with strains of Enterococcus faecium. Ireland, Cyprus, Greece, and Romania 
particularly report rates of vancomycin-resistant E. faecium higher than 25% (De 
Kraker et al., 2013; Versporten et al., 2014).  
Globally, the spread of MDR gram-positive organisms is limited due to various 
infection control measures and efficient interventions, e.g., hand hygiene campaigns 
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and reduced antibiotic selective pressure targeting gram-positive organisms (Eggimann 
& Pittet, 2001).  
Resistance to gram-negative pathogens is surprisingly increasing worldwide, leading to 
outbreaks in a few countries, e.g., Greece, Italy, India, and others. Interestingly, 
resistance to carbapenems and colistin is the most challenging condition in healthcare 
(Ferri, Ranucci, Romagnoli, & Giaccone, 2017). In addition, GNBs have the ability to 
acquire genetic mutations via transformation from other resistant strains to develop 
high-risk clones and spread in various environments (Pitout, Nordmann, & Poirel, 
2015).  
The consensus of clinical microbiologists is that MDR GNBs pose an extreme danger 
to public health. The increased resistance of GNB is largely due to moveable genes 
carried by plasmids that may readily spread through bacterial populations. Furthermore, 
human air travel and movement permit the swift transport of bacterial plasmids and 
clones among regions and continents. Most of this distribution remains unnoticed, with 
resistant clones residing as part of normal human microbiota and detected only when 
they culminate in an endogenous infection (Kumarasamy et al., 2010).  
Infections due to MDR gram-negative strains are associated with higher mortality rates 
(Vardakas, Rafailidis, Konstantelias, & Falagas, 2013) and fewer therapeutic choices. 
The last three options to treat MDR gram-negative infections are tigecycline, 
fosfomycin, and colistin. Despite the nephrotoxicity and neurotoxicity of colistin, it 
remains the drug of choice to treat fatal infections caused by MDROs, specifically in 
carbapenemase-endemic countries (Karageorgopoulos, Kelesidis, Kelesidis, & 
Falagas, 2008; Karaiskos & Giamarellou, 2014; Michalopoulos, Tsiodras, Rellos, 
Mentzelopoulos, & Falagas, 2005). Therefore, it is a serious option to limit multidrug 
resistance in gram-negative pathogens globally to optimize their therapeutic use in 
	
23 
treating life-threatening infections. Implementation of effective antimicrobial 
stewardship measures in community and healthcare settings can restrict the spread of 
MDR gram-negative pathogens worldwide. Timely delivery of antimicrobial diagnostic 
measures can play a synergistic role to achieve this goal (Roca et al., 2015).   
2.1.4 Antimicrobial Resistance in the Kingdom of Saudi Arabia  
As other continents, the KSA is at risk of AMR. Irrational antibiotics use and a large 
population of migrant workers specifically from the Indian subcontinent are the most 
prominent risk factors for the spread of MDR pathogens. In addition, antibiotic 
availability without prescription at the community pharmacy level positively 
contributes to inappropriate antibiotics use in the KSA (Emeka, Al-Omar, & Khan, 
2014; Zowawi, 2016; Zowawi, Balkhy, Walsh, & Paterson, 2013). Zowawi et al. 
reported the high prevalence of ESBL- and carbapenemase-producing GNBs in Gulf 
Cooperation Council countries, including the KSA (Zowawi et al., 2013). A study from 
Jeddah reported a rate of 31% of ESBL-producing E. coli and K. pneumonia isolated 
from intensive care units (Rotimi, Al-Sweih, & Feteih, 1998). Yezli et al. reported 
conversion of carbapenems in Enterobacteriaceae in the KSA. In addition, resistance 
among Pseudomonas aeruginosa is increasing (Saber Yezli, Shibl, Livermore, & 
Memish, 2014).  Furthermore, a study reported the finding of the mcr-1 gene in an E. 
coli strain from the KSA, Bahrain, and the United Arab Emirates (Sonnevend et al., 
2016). Similarly, the KSA national surveillance of gram-positive cocci revealed that 
32% of methicillin-resistant (MRSA) and 26% of Streptococcus pneumonia are 
resistant to erythromycin (Shibl et al., 2014).  
A study conducted in a tertiary care hospital in Riyadh of ventilator-associated 
pneumonia patients determined the involvement of the most common pathogens and 
their resistance to commonly available agents. Interestingly, the authors found that 
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Acinetobacter baumannii was a highly resistant pathogen among isolates. 
Pseudomonas aeruginosa was the least-resistant pathogen except that it was completely 
resistant to ampicillin (Balkhy et al., 2014).   
Mass congregations pose serious health hazards to attendees via the transmission of 
infectious diseases through contact, food or water contamination, respiratory droplets, 
and oral-faecal and vector-borne transmission. The potential for epidemics due to 
person-to-person contact and food- and water-borne disease eruptions may result in a 
rapid and broad geographic spread of diseases. Moreover, the introduction of non-
endemic diseases is a feared event during such assemblies. Imported, exported and 
endemic are probable disease patterns during such gatherings. The Hajj is a unique 
mass congregation associated with substantial international travel. Millions of pilgrims 
around the world travel to perform Hajj and Umrah rituals in the holy cities Makkah 
and Madinah in the KSA. Each year, more than 5 million pilgrims from 184 countries 
around the world participate in the Hajj or Umrah, and during the Hajj, a huge number 
of pilgrims gather in close vicinity to perform mandatory rituals. While the Hajj is one 
of the most common repeated mass congregations, Umrah is a ritual performed by 
pilgrims throughout the year. The transmission of drug-resistant organisms during the 
Hajj is not well described. This obligation increases the risk of potentially dangerous 
transmissible diseases in this population. The stress on healthcare systems during these 
two holy rituals is enormous, and the difficulty in the communication of risk due to 
language and cultural barriers makes the scenario particularly challenging (Al-Tawfiq 
& Memish, 2015).  
Recently, a systematic review conducted by Leangapichart et al. identified a high 
prevalence of third-generation cephalosporin-resistant bacteria among Makkah 
residents. In other studies, carbapenem-resistant bacteria were detected in K. 
